Fundraising Fox

Genghis Lloyd-Harris

Investor

Partner at Abingworth

London

Writes $15M – $30M checks · typically $22.5M

About

Genghis Lloyd-Harris is a Senior Advisor to Abingworth and formerly a Partner, where his work centered on exiting venture investments through M&A and IPOs. He joined Abingworth in 2004 from Credit Suisse First Boston, where he was a Managing Director in the European Equity Research Group in London covering the biotechnology industry, having earlier worked in CSFB's Health Care investment banking group in New York. He previously practiced as a paediatrician in Melbourne and holds a Medical Degree from the University of Liverpool, a PhD in Clinical Pharmacology from the University of Melbourne, and an MBA from Harvard Business School.

Invests in

Biotech

Experience

  1. Cancer Research HorizonsInvestor-In-Residencecurrent2023 — presentLondon
  2. ClotProtectChairmancurrent2024 — presentLeeds, UK
  3. Lean Life ScienceSenior Advisorcurrent2023 — presentManchester
  4. Harvard Medical SchoolReviewercurrent2024 — presentBoston, Massachusetts, United States
  5. AbingworthSenior Advisorcurrent2023 — presentLondon
  6. AbingworthPartner2004 — 2023London
  7. Credit Suisse First Boston (now UBS)Managing Director, Equity Research, Biotechnology1994 — 2004London
  8. Credit Suisse First Boston (now UBS)Vice President, Investment Banking, Pharma/Biotech1989 — 1994New York

Skills & more

Strategy3IPO25Venture Capital51Equities10Mergers6Investment Banking19Mergers & Acquisitions19Joint Ventures1Financial Modeling2Equity Research6Private Equity8Investments4
+12 moreFinancial AnalysisM&A experienceAsset ManagementDue DiligenceLBOBusiness StrategyCapital MarketsBiotechnologyEntrepreneurshipBloombergPharmaceutical IndustryBoard of Directors

From Genghis's professional profile.

Deals · 1

Gensight Biologics S.ABoard seat

via Abingworth · filed Jul 2015 · $25M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

AvillionGenSight BiologicsHealthcare Brands InternationalNouscomNovexelSolexaSynosiaSyntaxinWilson Therapeutics

Sources: the firm's website · SEC Form D filings.

Colleagues at Abingworth

Alex Asquith
Counsel at Abingworth
Amit Khasgiwala
Investment Professional at Innovatus Capital Partners
Andrew Sinclair
Managing Director, Head of Publics & Late Stage at Abingworth
Ankur Shah
Vice President, CCD at Abingworth
Anna Slezak
Senior Associate at Abingworth
Bali Muralidhar
Global Head of Life Sciences & CIO at Abingworth
Carlos Paya
Venture Partner at Ysios Capital
Dayle Hogg
Operating Executive at Abingworth

Network5

Andrew Sinclair
Managing Director, Head of Publics & Late Stage at Abingworth
Diya Malhotra
Principal at Abingworth
Jacqueline Grant
Principal at Abingworth
Jay Cui
Principal at Abingworth
Jayson Punwani
Managing Director, Head of Venture at Abingworth

Investors connected to Genghis in public investor directories — a warm-intro map.

Frequently asked questions

Who is Genghis Lloyd-Harris?
Genghis Lloyd-Harris is a Senior Advisor to Abingworth and formerly a Partner, where his work centered on exiting venture investments through M&A and IPOs. He joined Abingworth in 2004 from Credit Suisse First Boston, where he was a Managing Director in the European Equity Research Group in London covering the biotechnology industry, having earlier worked in CSFB's Health Care investment banking group in New York. He previously practiced as a paediatrician in Melbourne and holds a Medical Degree from the University of Liverpool, a PhD in Clinical Pharmacology from the University of Melbourne, and an MBA from Harvard Business School.
Where does Genghis Lloyd-Harris work?
Genghis Lloyd-Harris is Partner at Abingworth.
What does Genghis Lloyd-Harris invest in?
Genghis Lloyd-Harris invests in Biotech.
What check size does Genghis Lloyd-Harris write?
Genghis Lloyd-Harris typically writes checks of $15M – $30M.
What boards does Genghis Lloyd-Harris sit on?
Genghis Lloyd-Harris holds tracked board seats at Avillion, GenSight Biologics, Gensight Biologics S.A, Healthcare Brands International, Nouscom, Novexel, Solexa, Synosia, Syntaxin, Wilson Therapeutics.
Where did Genghis Lloyd-Harris go to school?
Genghis Lloyd-Harris studied at Harvard Graduate School of Business Administration (MBA); University of Melbourne (PhD, Clinical pharmacology); Liverpool University Medical School (MB ChB, Medicine and Surgery).

Same school

Also attended University of Melbourne231

Cameron AdamsCo-founder & Chief Product Officer of CanvaKevin JohnsonInvestor at MedicxiEsther GilmoreGlobal Head of the Client Team at Generation Investment ManagementMark MillsClient Team Member at Generation Investment ManagementPaulInvestor at Square Peg CapitalClarissa KartikaAssociate, Investment at Vertex Ventures Sea Management Pte. Ltd.

+ 225 more

Shared employers

Also worked at Cancer Research Horizons2

Carlos Garcia-EcheverriaVenture Partner at Ysios CapitalDeborah HarlandChair, LifeArc Ventures Investment Committee at LifeArc Ventures

Also worked at Harvard Medical School169

Logan HilleLife Sciences Analyst at CincyTechAnkit GuptaGeneral Partner at Y CombinatorDavid MollerInvestor at Third Rock VenturesJulie YangInvestor at Third Rock VenturesTracy WilliamsInvestor at Third Rock VenturesSamuel ArbesmanVenture Partner at Lux Capital

+ 163 more

Also worked at Abingworth18

Carlos PayaVenture Partner at Ysios CapitalSarah ShackeltonAdvisor at Delin VenturesBali MuralidharGlobal Head of Life Sciences & CIO at AbingworthKurt von EmsterManaging Partner at AbingworthJayson PunwaniManaging Director, Head of Venture at AbingworthAndrew SinclairManaging Director, Head of Publics & Late Stage at Abingworth

+ 12 more